Edwards Lifesciences 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Edwards Lifesciences reported 3rd quarter 2026 sales of $1.72 billion, up 11.2% year over year, and adjusted EPS of $0.80; both businesses and regions contributed to performance that exceeded expectations.
- TAVR sales were $1.2 billion, up 8.8%; TMTT sales were $207 million, up 45.6%; and Surgical sales were $264 million, up 3% year over year.
- Adjusted gross profit margin was 78.7%, compared with 77.9% a year earlier, and adjusted operating profit margin was 30.3%; GAAP EPS was $0.53, primarily reflecting impairment of a research and development asset.
- The company had approximately $3.1 billion in cash and cash equivalents as of September 30th, 2026, and repurchased approximately $700 million of shares through the 3rd quarter.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
As a reminder, this conference is being recorded. It is now my pleasure to introduce Gerianne Sarte, Senior Vice President, Investor Relations. Thank you. You may begin.
Good afternoon, and thank you for joining us. With me on today's call is our CEO, Bernard Zovighian, and our CFO, Doretta Mistras. Also joining us for the Q&A portion of the call will be Dan Lippis, our Global Leader of TAVR, and Daveen Chopra, who has global responsibility for TMTT, Surgical, and IHFM. After the close of regular trading, Edwards Lifesciences released third quarter 2026 financial results. During today's call, management will discuss the results included in the press release and accompanying financial schedules, and then use the remaining time for Q&A. Please note that management will be making forward-looking statements that are based on estimates, assumptions, and projections. These statements speak only as of the date on which they are made, and Edwards does not undertake any obligation to update them after today.
Additionally, the statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. Factors that could cause these differences can be found in today's press release and Edwards' other SEC filings, all of which are available on the company's website at edwards.com. Unless otherwise noted, our commentary on sales growth refers to underlying sales growth, which is defined in the financial results press release issued earlier today. Reconciliations between GAAP and non-GAAP numbers mentioned during this call are also included in today's press release. Quarterly and full-year growth rates refer to continuing operations. With that, I'll turn the call over to Bernard for his comments.
Thank you, Jerianne, and welcome, everyone. We delivered third quarter results that exceeded expectation, with both our businesses and regions driving strong broad-based performance. Even more importantly, we achieved meaningful progress on several of our most important clinical, regulatory, policy, and commercial priorities, strengthening our outlook for durable long-term growth. The consistency of our top-tier financial performance is a reflection of our focused strategy, as well as our commitment to innovation, speed and agility, and the strength of execution by our 17,000 dedicated employees across Edwards. Third quarter sales of $1.72 billion grew 11.2%. This performance was driven by our structural heart portfolio, including continuous strength in TAVR and growing contributions from our portfolio of TMTT therapies with PASCAL, EVOQUE, and SAPIEN M3.
Based on our strong performance this quarter, we are raising our full-year sales growth guidance to approximately 11.5% and our adjusted EPS guidance to $2.97-$3.05, growing 18% at the midpoint versus prior year. As I reflect on 2026 so far, I am proud of what our teams have accomplished and how we are positioning Edwards for the future. We are clear on our strategy focusing on structural heart, a large and growing space with significant unmet patient needs. We invest early, taking a long-term view with conviction to create entirely new categories of treatment that push the boundaries of what is possible for underserved patients. At the same time, we are moving with intention, sharpening how we are operating, embracing science and technology advancements, accelerating decision-making, and executing against an important set of priorities.
Our focus continues to deliver meaningful progress across the company, underpinned by our foundational patient-focused culture. All of this together sets us apart and is why we are confident in our long-term success. We are pleased to see our strategy deliver particularly impressive progress over the last few months, with five meaningful therapy approvals that offer new options to physicians. In addition, we continue to elevate the clinical evidence standard for structural heart care, including the release of two new practice-changing data sets. In TAVR, the SAPIEN platform continues to set the benchmark for valve performance and durability, supported by ongoing innovation and world-class clinical evidence. The PROGRESS trial marks a turning point in our collective understanding and management of moderate AS.
Taken all together, the PROGRESS trial results, EARLY TAVR clinical outcomes, and long-term cost-effectiveness data, and PARTNER 3 seven-year durability data are advancing the understanding of aortic stenosis as a disease and reinforcing the differentiation of TAVR with the SAPIEN platform as a compelling treatment strategy for CVAS. As a result, this changes how the clinical community looks at the disease, how to evaluate, who to treat, when to treat, and ultimately, this underscores the value of proactive disease management with the SAPIEN platform. In addition, the modernization of the NCD represents an important step toward expanding access to TAVR for timely, high-quality care for all AS patients. In TMTT, our years of pioneering development and strategic investment have resulted in a portfolio of therapies allowing our teams a unique opportunity to collaborate with physicians to personalize care for the clinically diverse patients suffering from mitral and tricuspid diseases.
With the recent U.S. approvals of PASCAL for tricuspid patients and next-generation Capture Clarity for mitral patients, we are further strengthening the portfolio of treatment options. In surgical, we continue to see strong adoption of our RESILIA portfolio of therapies, and we continue to introduce new therapies to address unmet patient needs, including AUTUS for congenital patient and ECLIPTIS for surgical left atrial appendage occlusion. At the same time, we are applying our proven innovation playbook to new areas of significant unmet need within structural heart, including structural heart failure and aortic regurgitation, creating additional opportunities for long-term growth. When I reflect on all of this, I am proud of our impact. When Edwards leads, everyone benefits: physician, providers, payers, and most importantly, patients, who enjoy a restored quality of life and live longer. Now, let's dive a little deeper into the recent presentation at TCT.
Physicians presented compelling new evidence on SAPIEN, PASCAL, EVOQUE, and SAPIEN M3 that deepens the clinical community's understanding of these therapies and underscores their significant potential to transform care for AS, mitral, and tricuspid patients. The breadth and quality of this evidence reflects the strength of our innovation strategy and our commitment to setting the benchmark for clinical evidence in structural heart disease. Putting all of this in perspective, these advancements represent meaningful multi-year opportunities that we expect to build over time and which underpin our long-term growth target of approximately 10% average annual sales growth alongside leveraged EPS growth. Now, I will provide more detail about the performance of our product groups. TAVR third quarter global sales of $1.2 billion were stronger than expected and increased 8.8% over the prior year. Edwards' growth rate were similar in the U.S. and outside of the U.S.
Globally, procedural growth benefited from a heightened focus on TAVR and data supporting proactive disease management of severe AS. Exiting Q3, we saw encouraging signs of procedure growth. After several quarters of modest share gains, we are pleased with how our competitive position supported by our differentiated SAPIEN platform has contributed to year-to-date TAVR performance. Average selling prices were stable globally. At TCT, results from the PROGRESS trial were presented and published in The New England Journal of Medicine, marking a turning point in the management of moderate AS. The remarkable performance and unparalleled safety of the SAPIEN platform, coupled with the superior trial results, validate TAVR as a treatment strategy for moderate AS patients with at-risk features.
These findings challenge the longstanding assumption that moderate AS patients can be managed by the current practice of passive surveillance and encourages the clinical community to embrace earlier referral to a valve clinic for comprehensive testing and advanced management for optimal outcomes. PROGRESS builds on Edwards' decade-long commitment to generating rigorous clinical evidence that advances the understanding of the serious impact and unpredictable progression of aortic stenosis and continues to validate the patient benefit of proactive disease management. Also presented at TCT was ACTIVATE, a large real-world investigator-initiated study of more than 53,000 patients with AS who were identified within advanced healthcare system using EHR. The study demonstrated that patients with moderate AS outnumber those with severe AS nearly two to one. Additionally, among the patients with moderate AS, approximately 80% had at least one at-risk feature, which was associated with an increased risk of death and hospitalization.
The evidence from PROGRESS and ACTIVATE suggests that the in-system and out-of-system moderate opportunity is at least as large as the severe AS opportunity. We will continue to share our perspectives on the moderate patient opportunity as the evidence continues to grow and the clinical community gains experience managing this patient over time. Additionally, new long-term economic data from the EARLY TAVR trial reinforced the value of proactive disease management. In patients with asymptomatic severe aortic stenosis, Edwards TAVR delivered exceptional economic value compared with clinical surveillance and remain highly cost-effective even after accounting for potential future valve reintervention. Notably, this result we achieved in a highly controlled trial setting where patient benefited from optimal care and treatment with a median time to intervention of just 32 days, compared with approximately 157 days observed in real-world practice.
Taken together, the practice-changing EARLY TAVR and PROGRESS studies deepen our understanding of aortic stenosis and continue to validate the patient benefit of proactive disease management. This evidence is now clear that intervening before the disease progresses avoids significant health decline and serious cardiovascular events, such as heart failure-related hospitalization and death. Let me now turn to some commentary on U.S. TAVR. In Q3, procedure growth continued to benefit from a heightened focus on TAVR therapy as the clinical community further incorporates into practice the meaningful evidence supporting proactive disease management. Edwards' competitive position in the U.S. was stable sequentially and increased modestly year over year, enabled by strong adoption of our differentiated SAPIEN 3 Ultra RESILIA. During the quarter, CMS released the final updated NCD for TAVR.
We are pleased that the updated policy represents an important step toward improving and expanding timely, high-quality access to care while reinforcing the value of a multidisciplinary heart team. We believe there are four important elements within the NCD. First, the policy will enable greater flexibility for the heart team at every step of a patient journey, from evaluation to treatment. Second, it will support appropriate site expansion over time for updated hospital procedure volume requirements. Third, the NCD will expand coverage to asymptomatic patients. And finally, the policy provides a pathway to coverage for Medicare Administrative Contractors, or MACs, to address reasonable and necessary coverage when future TAVR indications are approved.
Taken together, these changes establish a strong foundation that will expand timely, high-quality access to care, support the continued evolution of TAVR, and ensure that more patients with aortic stenosis will benefit from treatment for many years to come. Outside of the U.S., we continue to see strong adoption of our SAPIEN technology. In Europe, updated ESC and EACTS guidelines are helping shape clinical discussion around earlier intervention and proactive disease management, further reinforcing the role of TAVR across a broader patient population. Edwards' competitive position increased modestly year over year in Europe. In Japan, we continue to be encouraged by the growth and the continued adoption of SAPIEN 3 Ultra RESILIA. Also in Japan, we secured new and dedicated reimbursement for SAPIEN 3 Ultra RESILIA, which recognizes the value of our innovation and helped contribute to Japan's strong performance in the quarter.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
12 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
